$2.76
3.37%
Nasdaq, Sep 18, 04:00 pm EDT. Closed.
ISIN
US30233M1071
Symbol
KPRX

EyeGate Pharmaceuticals, Inc. Target price 2026 - Analyst rating & recommendation

EyeGate Pharmaceuticals, Inc. Classifications & Recommendation

Buy
86%
Hold
14%

EyeGate Pharmaceuticals, Inc. Price Target

Target Price $12.24
Price $2.76
Potential
Number of Estimates 3
3 Analysts have issued a price target EyeGate Pharmaceuticals, Inc. 2027 . The average EyeGate Pharmaceuticals, Inc. target price is $12.24. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 7 analysts: 6 Analysts recommend EyeGate Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the EyeGate Pharmaceuticals, Inc. stock has an average upside potential 2027 of . Most analysts recommend the EyeGate Pharmaceuticals, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Earnings Per Share $ -2.60 -1.70
398.85% 34.62%
P/E negative

3 Analysts have issued a EyeGate Pharmaceuticals, Inc. forecast for earnings per share. The average EyeGate Pharmaceuticals, Inc. EPS is

$-1.70
unlock
. This is
3.95% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-1.75 1.13%
unlock
, the lowest is
$-1.64 7.34%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-2.60 398.85%
2026
$-1.70 34.62%
unlock
2027
$-0.87 48.82%
unlock
2028
$-0.98 12.64%
unlock

P/E ratio

Current -1.56 77.19%
2026
-1.62 3.89%
unlock
2027
-3.18 96.30%
unlock
2028
-2.82 11.32%
unlock

Current EyeGate Pharmaceuticals, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Sep 02 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 28 2025
HC Wainwright & Co.
Locked
Locked
Locked Nov 12 2024
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Sep 02 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 28 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Nov 12 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today